High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies
Year: 2022
Type: article
Authors: Boglarka Gyurkocza, Rajneesh Nath, Stuart E. Seropian, Hannah Choe, Mark R. Litzow, Nebu Koshy, Patrick Stiff, Camille Abboud, Benjamin Tomlinson, Sunil Abhyankar, Parameswaran Hari, George L Chen, Zaid Al-Kadhimi, Mitchell Sabloff, Johnnie J. Orozco, James Foran, Partow Kebriaei, Katarzyna Jamieson, Margarida Magalhaes-Silverman, Koen van Besien, Michael W Schuster, Arjun Datt Law, Moshe Yair Levy, Hillard M. Lazarus, Sergio A Giralt, Mark S. Berger, Jennifer Spross, Avinash Desai, Vijay Reddy, John M. Pagel
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W4221064371